UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

        CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                           AND EXCHANGE ACT OF 1934.

                                November 18, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

         Utah                                                 59-2780520
(State of Incorporation)                               (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

      On November 18, 2005, the Registrant  issued to Dutchess  Private Equities
Fund,  L.P.  ("Dutchess")  a  promissory  note  (the  "Note")  in the  amount of
$1,380,000 for a purchase price of $1,150,000.

      As previously reported, on September 28, 2004, the Registrant entered into
an  Investment  Agreement  (the  "Investment  Agreement")  with an  affiliate of
Dutchess,  pursuant to which Dutchess has committed to purchase  common stock of
the Registrant up to an aggregate  purchase price of $35 million over a two year
period.  The Dutchess  Agreement  provides that the Registrant from time to time
may deliver a put notice to  Dutchess,  and  Dutchess is obliged to purchase the
dollar amount of common stock set forth in the notice.

      The Note is due and payable in full on December 31,  2006.  Other than the
discount  inherent in its purchase price, the Note is  noninterest-bearing.  The
Note will be repaid using 100% of the  proceeds of each put notice  delivered by
the Registrant to Dutchess under the Investment  Agreement.  The Registrant also
entered into a Security  Agreement with Dutchess granting a security interest in
substantially all of the Registrant's assets to secure payment of the Note.

      In connection  with the Note, the Registrant also paid Dutchess a facility
fee of  $65,000  and  issued to  Dutchess  a  non-interest  bearing  convertible
debenture in the amount of $330,000  payable on November 18, 2010. The shares of
common stock underlying the debenture carry piggyback  registration  rights. The
debenture may be converted at Dutchess's  option at a conversion  price equal to
the lesser of 75% of the lowest  closing  bid price  during the 15 trading  days
prior to the conversion date or $0.013.

Item 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN  OBLIGATION  UNDER
          AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.

<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                                DNAPrint genomics, Inc.

                                                By:/s/ Richard Gabriel
                                                  ---------------------------
                                                  Richard Gabriel, President
{"company-data": {"conformed-name": "DNAPRINT GENOMICS INC", "cik": "0001127354", "assigned-sic": "8731", "irs-number": "592780520", "state-of-incorporation": "UT", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-31905", "film-number": "051226966"}, "business-address": {"street1": "900 COCONUT AVE.", "city": "SARASOTA", "state": "FL", "zip": "34231", "phone": "9413663400"}, "mail-address": {"street1": "900 COCOANUT AVENUE", "street2": "NO SUITE", "city": "SARASOTA", "state": "FL", "zip": "34231"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

        CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                           AND EXCHANGE ACT OF 1934.

                                November 18, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

         Utah                                                 59-2780520
(State of Incorporation)                               (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

      On November 18, 2005, the Registrant  issued to Dutchess  Private Equities
Fund,  L.P.  ("Dutchess")  a  promissory  note  (the  "Note")  in the  amount of
$1,380,000 for a purchase price of $1,150,000.

      As previously reported, on September 28, 2004, the Registrant entered into
an  Investment  Agreement  (the  "Investment  Agreement")  with an  affiliate of
Dutchess,  pursuant to which Dutchess has committed to purchase  common stock of
the Registrant up to an aggregate  purchase price of $35 million over a two year
period.  The Dutchess  Agreement  provides that the Registrant from time to time
may deliver a put notice to  Dutchess,  and  Dutchess is obliged to purchase the
dollar amount of common stock set forth in the notice.

      The Note is due and payable in full on December 31,  2006.  Other than the
discount  inherent in its purchase price, the Note is  noninterest-bearing.  The
Note will be repaid using 100% of the  proceeds of each put notice  delivered by
the Registrant to Dutchess under the Investment  Agreement.  The Registrant also
entered into a Security  Agreement with Dutchess granting a security interest in
substantially all of the Registrant's assets to secure payment of the Note.

      In connection  with the Note, the Registrant also paid Dutchess a facility
fee of  $65,000  and  issued to  Dutchess  a  non-interest  bearing  convertible
debenture in the amount of $330,000  payable on November 18, 2010. The shares of
common stock underlying the debenture carry piggyback  registration  rights. The
debenture may be converted at Dutchess's  option at a conversion  price equal to
the lesser of 75% of the lowest  closing  bid price  during the 15 trading  days
prior to the conversion date or $0.013.

Item 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN  OBLIGATION  UNDER
          AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                                DNAPrint genomics, Inc.

                                                By:/s/ Richard Gabriel
                                                  ---------------------------
                                                  Richard Gabriel, President